IGF1 and amyotrophic lateral sclerosis: Human mutations which influence hepatic IGF-1 or binding protein or ALS [114] dramatically reduce serum IGF-I concentrations but do not result in significant growth impairment in contrast to tissue-wide IGF-1 gene deletions [115].